DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS | Zendy

Howard Trachtman | Zendy; Peter J. Nelson | Zendy; Sharon G. Adler | Zendy; Kirk N. Campbell | Zendy; Abanti Chaudhuri | Zendy; Vimal K. Derebail | Zendy; Giovanni Gambaro | Zendy; Loreto Gesualdo | Zendy; Debbie S. Gipson | Zendy; Jonathan Hogan | Zendy; Kenneth V. Lieberman | Zendy; Brad A. Marder | Zendy; Kevin Meyers | Zendy; Esmat Mustafa | Zendy; Jai Radhakrishnan | Zendy; Tarak Srivastava | Zendy; Miganush Stepanians | Zendy; Vladimı́r Tesař | Zendy; Olga Zhdanova | Zendy; Radko Komers | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS

Author(s) -

Howard Trachtman,

Peter J. Nelson,

Sharon G. Adler,

Kirk N. Campbell,

Abanti Chaudhuri,

Vimal K. Derebail,

Giovanni Gambaro,

Loreto Gesualdo,

Debbie S. Gipson,

Jonathan Hogan,

Kenneth V. Lieberman,

Brad A. Marder,

Kevin Meyers,

Esmat Mustafa,

Jai Radhakrishnan,

Tarak Srivastava,

Miganush Stepanians,

Vladimı́r Tesař,

Olga Zhdanova,

Radko Komers

Publication year - 2018

Publication title -

journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.451

H-Index - 279

eISSN - 1533-3450

pISSN - 1046-6673

DOI - 10.1681/asn.2018010091

Subject(s) - irbesartan , medicine , urology , valsartan , creatinine , clinical endpoint , angiotensin ii , endothelin receptor antagonist , endothelin receptor , renal function , angiotensin receptor , glomerulosclerosis , randomized controlled trial , gastroenterology , endocrinology , kidney , receptor , proteinuria , blood pressure

We evaluated and compared the effects of sparsentan, a dual endothelin type A (ET A ) and angiotensin II type 1 receptor antagonist, with those of the angiotensin II type 1 receptor antagonist irbesartan in patients with primary FSGS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research